hematologic malignancies after umbilical cord blood transplantation
Conditions
Interventions
rhTPO (for the first time + maintenance) treatment group:Patients are treated with rhTPO 300u/kg in 6 hours after UCBT and from +14d~+28d after UCBT
rhTPO maintenance treatment group:patients are treated with rhTPO 300u/kg from +14d~+28d after UCBT
Blank control group:No rhTPO usage
Sponsors
Department of Hematology, Anhui Provincial Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients were diagnosed withhematologic malignancies, weight more than 30kg, Any age, any gender, any race; 2. Voluntary acceptance of UCBT; 3. Voluntary acceptance of rhTPO open randomized controlled study; 4. Each participant must sign a consent form (ICF), shows that he/she understand the study purpose and procedures, and are willing to participate in research;Considering from the patient, if the signature is not conducive to patient treatment, it is signed by the legal representative of ICF.
Exclusion criteria
Exclusion criteria: 1. Serious viscera dysfunction or disease, such as serious diseases and function disorder in heart, liver, kidney and pancreas; 2. Can not tolerate rhTPO subcutaneous injection; 3. Participants and/or authorized family members refused to accept UCBT and rhTPO therapy; 4. Researchers believe that can damage the unnecessary risks to safety, make the results of the study subjects any life-threatening illness, condition or organ system dysfunction; drug dependence; uncontrolled mental disease; cognitive impairment; 5. Participate in other similar clinical researches in 3 months; 6. Researchers think that the patient doesn't fit into the group (e.g., patients are expected to be discontinue because of funding problems).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Platelet implantation time; | — |
Secondary
| Measure | Time frame |
|---|---|
| Platelet transfusion units;Neutrophil implantation time;Platelet recovery rate;Neutrophil recovery rate;Cumulative incidence of II~IV,III~IV acute GVHD rate;180d transplant related mortality;relapse rate;one year overall survival;one year leukemia free survival; | — |
Contacts
Public ContactXiaoyu Zhu
Anhui Provincial Hospital
Outcome results
None listed